Evaluation of the Combination of Metformin and Rapamycin in an MPP(+)-Treated SH-SY5Y Model of Parkinson's Disease

Metformin (MET) and rapamycin (RAPA) have been reported to protect against neurodegeneration in cellular and animal models of Parkinson's disease (PD). MET, which is a first-line drug for type 2 diabetes, and RAPA are known as mTORC1 inhibitors. MET also acts as an AMPK activator, which leads t...

Descripción completa

Detalles Bibliográficos
Autores principales: Norradee, Chureerat, Khwanraj, Kawinthra, Balit, Tatcha, Dharmasaroja, Permphan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870674/
https://www.ncbi.nlm.nih.gov/pubmed/36698448
http://dx.doi.org/10.1155/2023/3830861

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870674/
https://www.ncbi.nlm.nih.gov/pubmed/36698448
http://dx.doi.org/10.1155/2023/3830861

Ejemplares similares